Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alladapt Immunotherapeutics, Inc.
This study is enrolling participants by invitation only. This is a multicenter, open-label, long-term extension study of the safety and efficacy of ADP101 for oral immunotherapy in food allergic children and adults who completed the Harmony study (protocol ADP101-MA-01).
Age
4–57
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must have completed the ADP101-MA-01 (The Harmony Study) and been compliant with study drug per protocol
You may not be if
History of or current EoE, other eosinophilic gastrointestinal disease, chronic, recurrent or severe GERD, symptoms of dysphagia
Hypersensitivity to epinephrine or any of the excipients in ADP101
Prior or concurrent therapies as follows:
* beta-blockers, ACE inhibitors, ARBs or calcium channel blockers
* regular steroid medication use
* therapeutic antibody treatment currently or within the previous 6 months
* any food immunotherapy currently or within the previous 12 weeks, except ADP101
* investigational agents other than ADP101
* in the build up phase of non-food immunotherapy
Any other condition that might preclude safe participation in the study
